MAPT and Alzheimer disease: Background/Objectives: Alzheimer’s disease (AD) is currently diagnosed using established biomarkers, such as reduced cerebrospinal fluid (CSF) Aβ42, increased phosphorylated tau, and cerebral amyloid levels detected by PiB-PET.